Hormone receptor positive breast cancer+1
RecruitingStudy of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer
- Disease:Hormone receptor positive breast cancerHormone receptor positive HER2 negative breast cancer
- Substances:CapecitabinePaclitaxel+4
Poland- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Merck Sharp & Dohme LLC










